Roche's pRED Leaders On Its Next Generation Of Drugs
Executive Summary
"We're not resting on our laurels," pRED head William Pao said in an early R&D overview. The company's R&D leaders highlighted drugs in oncology, neuroscience and ophthalmology.
You may also be interested in...
Up Next For Roche In Ophthalmology: Nine Clinical-Stage Programs
Roche said it remains deeply committed to the therapeutic area and highlighted a broad clinical pipeline at a virtual investor event.
Open-Label Extensions The Key To Gantenerumab Success, Stresses Roche
Roche’s neuroscience strategy of following the science, taking on lessons from open label extensions from Phase III studies, is vital to the success of gantenerumab, the company said in an interview with Scrip.
Just What We Were Looking For: Roche Pays €70m For Preclinical Anti-CD25 Asset
Roche acquires Tusk Therapeutics of the UK for its lead asset; its other activities will continue as Black Belt Therapeutics. Roche sees combo future for Tusk’s cancer immunotherapy with its own portfolio. Total deal value could reach €655m.